分析循环肿瘤 DNA (ctDNA)、循环肿瘤细胞 (CTC) 和骨髓疾病作为治疗血液癌症患者的辅助工具的用途正在扩大。这对于淋巴瘤来说也是如此，人们正在探索这些生物标志物作为基因分型和量化疾病的手段。对于后者，它们可用于监测治疗期间和治疗后的可测量残留病灶（MRD）。这有可能帮助治疗过程中的临床决策、检测早期复发和改善预后。在这里，我们回顾了支持这些在各种淋巴瘤亚型中应用的证据。针对各种淋巴瘤的大量临床试验已经证明了 MRD 监测的价值。 MRD 监测通常可预测病程中多个时间点的无进展生存期 (PFS) 甚至总生存期 (OS)，特别是在使用连续测量时。关于定制治疗，越来越多的试验检验 MRD 适应性治疗策略，以加强或降级治疗以实现个体化护理。最后，与放射线评估等更标准的临床监测方法相比，MRD 监测已成功用于检测早期复发。虽然淋巴瘤的 MRD 监测并未常规应用于临床实践，但它通过帮助预测、指导治疗和检测早期复发，正在帮助塑造这种疾病的未来格局。我们正在采取标准化措施并进一步前瞻性地研究该技术，以便将 MRD 监测推向该领域的前沿。© 2023。作者获得 Springer Science Business Media, LLC（Springer Nature 旗下公司）的独家许可。

The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as an adjunctive tool in caring for hematologic cancer patients is expanding. This holds true for lymphoma where these biomarkers are being explored as a means of genotyping and quantifying disease. Regarding the latter, they can be used to monitor measurable residual disease (MRD) during and after treatment. This holds potential for aiding clinical decisions amidst treatment, detecting earlier relapse, and improving prognostication. Here, we review the evidence to support these applications in a variety of lymphoma subtypes.Numerous clinical trials across a variety of lymphomas have demonstrated value in MRD monitoring. MRD monitoring is often prognostic for progression free survival (PFS) and even overall survival (OS) at several time points in a disease course, particularly when utilizing serial measurements. With regards to tailoring treatment, there are a growing number of trials examining MRD-adaptive treatment strategies to intensify or de-escalate treatment to individualize care. Lastly, MRD monitoring has been utilized successfully in detecting earlier relapse when compared to more standard methods of clinical surveillance such as radiographic assessment. Although not routinely implemented into clinical practice, MRD monitoring in lymphoma is helping shape the future landscape of this disease by aiding in prognostication, guiding therapy, and detecting earlier relapse. Steps to standardize and further examine this technology prospectively are being taken to bring MRD monitoring to the forefront of the field.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.